Sakai K - Search Results

1

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).

Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T. Watanabe S, et al. Among authors: sakai k. Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204. Cancers (Basel). 2022. PMID: 36612200 Free PMC article.

2

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Sakai K, et al. Cancer Sci. 2007 Sep;98(9):1498-503. doi: 10.1111/j.1349-7006.2007.00553.x. Epub 2007 Jul 11. Cancer Sci. 2007. PMID: 17627612 Free PMC article.

3

Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.

Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K. Kasahara K, et al. Among authors: sakai a, sakai k. Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2. Clin Cancer Res. 2010. PMID: 20679350

4

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Takeda M, Okamoto I, Sakai K, Tanaka K, Terashima M, Nishio K, Nakagawa K. Takeda M, et al. Among authors: sakai k. Clin Lung Cancer. 2012 Mar;13(2):157-9. doi: 10.1016/j.cllc.2011.09.003. Epub 2011 Nov 6. Clin Lung Cancer. 2012. PMID: 22056890 No abstract available.

5

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.

Sakai K, Okamoto I, Takezawa K, Hirashima T, Kaneda H, Takeda M, Matsumoto K, Kimura H, Fujita Y, Nakagawa K, Arao T, Nishio K. Sakai K, et al. J Thorac Oncol. 2012 May;7(5):913-8. doi: 10.1097/JTO.0b013e31824c7f7a. J Thorac Oncol. 2012. PMID: 22722791 Free article.

6

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.

Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Okamoto W, et al. Among authors: sakai k. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22. Mol Cancer Ther. 2012. PMID: 22729845

7

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.

Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Tanizaki J, et al. Among authors: sakai k. Clin Cancer Res. 2012 Nov 15;18(22):6219-26. doi: 10.1158/1078-0432.CCR-12-0392. Epub 2012 Jul 27. Clin Cancer Res. 2012. PMID: 22843788

8

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.

Hayashi H, Okamoto I, Kimura H, Sakai K, Nishimura Y, Nishio K, Nakagawa K. Hayashi H, et al. Among authors: sakai k. Anticancer Res. 2012 Oct;32(10):4533-7. Anticancer Res. 2012. PMID: 23060582

9

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Sakai K, et al. Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1. Cancer Sci. 2013. PMID: 23721103 Free PMC article.

10

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.

Terashima M, Fujita Y, Togashi Y, Sakai K, De Velasco MA, Tomida S, Nishio K. Terashima M, et al. Among authors: sakai k. Oncotarget. 2014 Aug 30;5(16):7040-50. doi: 10.18632/oncotarget.2220. Oncotarget. 2014. PMID: 25051373 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,061 results

Search Page

Filters